Figure 1.
Selection of novel and publicly available EBV genomes for analysis. (A) Schematic illustrating the source, histologic type, and number of EBV+ hematologic malignancies from Guatemala, Peru, Malawi, Taiwan, and the United States that underwent EBV-genome sequencing and the source of publicly available reference and cancer-associated EBV genomes that were utilized for this study. (B) Maps demonstrating the country of origin and number of EBV genomes after filtering based on sequence quality. Publicly available EBV genomes are indicated in black, and novel EBV genomes generated by this study are indicated in red. CAEBV, chronic active EBV disease; GC, gastric cancer; IM, infectious mononucleosis; misc, miscellaneous; PTLD, posttransplant lymphoproliferative disorder; QC, quality control.

Selection of novel and publicly available EBV genomes for analysis. (A) Schematic illustrating the source, histologic type, and number of EBV+ hematologic malignancies from Guatemala, Peru, Malawi, Taiwan, and the United States that underwent EBV-genome sequencing and the source of publicly available reference and cancer-associated EBV genomes that were utilized for this study. (B) Maps demonstrating the country of origin and number of EBV genomes after filtering based on sequence quality. Publicly available EBV genomes are indicated in black, and novel EBV genomes generated by this study are indicated in red. CAEBV, chronic active EBV disease; GC, gastric cancer; IM, infectious mononucleosis; misc, miscellaneous; PTLD, posttransplant lymphoproliferative disorder; QC, quality control.

Close Modal

or Create an Account

Close Modal
Close Modal